Surgical sealant film manufacturer Tissuemed, Leeds, has announced that its revenues have grown for the sixth consecutive quarter thanks to raised awareness among surgeons and clinical evidence demonstrating that they are addressing an unmet surgical need.
Over the last year the company has seen significant growth and as reported a 100% growth in sales, compared the same period last year.
Tissuemed manufactures very fine absorbable films branded ‘TissuePatch’ which adhere to the body’s internal tissues. By using TissuePatch, surgeons can prevent leakage of air, blood or other fluids that traditional stitches may not always contain without adjunctive support.
Sustained revenue growth may be common among medical device suppliers with a more established track record; however what is striking in Tissuemed’s case is that the company’s sales consist entirely of products which are novel and in some cases demand changes of surgical practice.
Speaking about Tissuemed’s success, CEO Nick Woods said: “TissuePatch products require no preparation, are very easy to use and work within 30 seconds of application.”
“We now have several independent clinical case studies, coupled with ongoing clinical studies in three prestigious Neurosurgical centres across Europe. This clinical evidence helps to demonstrate that we are addressing an unmet need. The avoidance of post- operative complications due to leakage is naturally highly desirable for patients. It also has the potential to reduce costs associated with extended in-patient duration and even more costly reoperations.”
For more information visit
www.tissuemed.com